Amgen To Pay Hospital $186M Over Royalties
Amgen, based in Thousand Oaks, Calif., has agreed to end future North American royalty payments for Enbrel, which is used to treat rheumatoid arthritis and psoriasis. The hospital will continue to receive royalties from Enbrel sales outside North America.
The drug’s combined royalty brought in nearly 75% of Massachusetts General’s $90 million in licensing fees...
To view the full article, register now.